ERBB2 and breast carcinoma: For example, Burguin et al. showed that HER2−/pHER2Y877+ breast cancer cells were sensitive to trastuzumab, therefore suggesting that patients without any molecular alterations in HER2 but a pHER2+ profile might benefit from an anti-HER2 targeted therapy [146].